Before we get started we’d like to remind you that this conference call contains forward-looking statements regarding future events and the future performance of Theravance. Forward-looking statements include anticipated results and other statements regarding Theravance’s goals, expectations, strategy and beliefs. These statements are based upon the information available to the company today and Theravance assumes no obligation to update these statements as circumstances change.Future events and actual results could differ materially from those projected in the company’s forward-looking statements. Additional information concerning factors that could cause results to differ materially from our forward-looking statements are described in greater detail in the company’s Form 10Q filed with the Securities & Exchange Commission.
These past few weeks have been very exciting for Theravance with important developments in our respiratory programs partnered with GSK and our peripheral Mu Opioid receptor antagonist TD-1211 opioid induced constipation or (OIC). Let me begin with our respiratory programs which are partnered with GSK starting with FF/VI, with the proposed brand name Relvar in the European Union and Breo in the United States. FF/VI is an investigational once a day inhaled combination medicine comprised of fluticsone furoate an inhaled corticosteroid and vilanterol a long acting Beta2 agonist or LABA for the maintenance treatment of chronic obstructive pulmonary disease or COPD and asthma. GSK and Theravance recently reached a major milestone with the submission of regulatory applications for FF/VI. For the treatment of COPD, GSK filed for the 125 dose of FF/VI in the US and the EU. For the treatment of asthma GSK filed for both the 100/25 microgram and the 200/25 microgram doses of FF/VI in the EU. For asthma in the US, GSK and Theravance are reviewing the strategy for a future filing. For both indications FF/VI would be administered by a new dry powder inhaler with the proposed brand name Ellipta.